



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
Phone: 022-24822222/24930918 Fax : 022 – 2493 0534/ 2493 9633
CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2016

(Rs. in lakhs)

Sl.No.	Particulars	Quarter ended	
		30-06-2016	30-06-2015
		Unaudited	Unaudited
1	Income from Operations		
	a. Net sales (Net of excise duty)	30,078.68	27,914.93
	b. Other Operating Income	843.87	505.92
	Total Income from Operations (Net) (a+b)	30,922.55	28,420.85
2	Expenses		
	a. Cost of materials consumed	9,555.32	9,022.98
	b. Purchases of stock-in-trade	2,135.01	2,309.10
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(174.06)	599.54
	d. Employees benefits expense	4,620.50	4,058.37
	e. Depreciation and amortization expense	1,131.66	977.00
	f. Exchange Fluctuation Transactional (Gain)/Loss	(3.27)	118.72
	g. Other Expenses	7,739.16	7,322.46
	Total Expenses	25,004.32	24,408.17
3	Profit from Operations before Other Income, Finance Cost (1-2)	5,918.23	4,012.68
4	Other Income	1,096.72	1,103.16
5	Profit before Finance Cost (3+4)	7,014.95	5,115.84
6	Finance Cost	77.88	197.83
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	6,937.07	4,918.01
8	Exchange Fluctuation Translation Gain / (Loss)	(128.74)	406.66
9	Profit before Tax (7-/+8)	6,808.33	5,324.67
10	Tax expenses	1,822.82	1,360.89
11	Net Profit/(Loss) after Tax (9-10)	4,985.51	3,963.78
12	Other Comprehensive Income (net of Tax)	(8.07)	(7.74)
13	Total Comprehensive Income after Tax (11+12)	4,977.44	3,956.04
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.16
15	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)		
	(1) Basic	5.88	4.67
	(2) Diluted	5.88	4.67

Notes:

- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 26, 2016.
- The financial results for the quarter ended June 2016 and June 2015 have been prepared in accordance with new accounting standards prescribed under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) applicable to the Company w.e.f. April 1, 2016.
- The auditors have carried out limited review of the above results for the quarter ended June 2016. Ind As compliant financial results for the quarter ended June 2015 have not been subjected to limited review. However, the management has exercised necessary due diligence to ensure that the financial results for the said quarter provide a true and fair view of the affairs of the Company.
- The reconciliation between net profit for the quarter ended June 2015 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS is as under:

(Rs. in lakhs)

Net profit reported for June 2015 as per previous Indian GAAP	3,428.19
Add/(Less) : Adjustments	
Actuarial loss on defined benefit plans reclassified to other comprehensive Income	11.84
Net gain arising on fair valuation of Investments	657.89
Net gain arising on fair valuation of Forward Contracts	8.02
Others	13.73
Deferred Tax Impact on above Adjustments	(155.89)
Net Profit after Tax as per Ind AS	3,963.78

- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai
Date : August 26, 2016

J.B.Mody
Chairman & Managing Director